Is Ibogaine Legal in the US? Federal Status, State Research, and Key Risks

Is Ibogaine Legal in the United States? The Short Answer

No, ibogaine is not legal for general use in the United States. Under federal law, ibogaine is classified as a Schedule I controlled substance by the Drug Enforcement Administration (DEA). This means it is illegal to manufacture, possess, distribute, or prescribe ibogaine outside of tightly regulated research settings. The US Food and Drug Administration (FDA) has not approved ibogaine for any medical use. This article provides general information and should not be interpreted as legal advice.

Some states, such as Texas, have recently appropriated funds for ibogaine research, but these initiatives do not legalize clinical use for the general public. Researchers, clinicians, and investors should be aware of the strict federal controls and the evolving state-level interest in ibogaine science.

Federal Law: Schedule I Status and Its Implications

Ibogaine is listed as a Schedule I substance under the Controlled Substances Act (CSA). Schedule I is the most restrictive category and is reserved for substances that:

• Have a high potential for abuse
• Have no currently accepted medical use in treatment in the United States
• Lack accepted safety for use under medical supervision

Other Schedule I psychedelics include LSD, psilocybin, and MDMA. Schedule I status makes it a federal crime to possess, manufacture, or distribute ibogaine except as part of an approved research protocol with specific DEA and FDA permissions. Violation can result in severe criminal penalties.

For a broader understanding of psychedelic scheduling and its impact on research, see our psychedelic law explainer and research landscape overview.

FDA Approval Status and Research Pathways

The FDA has not approved ibogaine for any therapeutic use. There are currently no FDA-authorized clinical trials of ibogaine for treatment of addiction or any other condition in the US. Any clinical research involving ibogaine requires both an Investigational New Drug (IND) application from the FDA and a Schedule I research license from the DEA, both of which are difficult to obtain.

In October 2026, the FDA signaled increased interest in ibogaine by seeking public input on research involving the compound. This move suggests a growing federal engagement with psychedelic science, but it does not change ibogaine's legal status or open any clinical access pathways at this time.

For more on the FDA's evolving approach to psychedelics, see our briefing feed and beginner's guide to psychedelic research.

State-Level Research Appropriations: Texas and Beyond

While federal law governs the core legality of ibogaine, some states have begun to support research into its potential therapeutic uses. The most notable example is Texas:

• Texas (SB 2308): In 2025, Texas appropriated approximately $50 million for research on ibogaine and related psychedelics. This funding supports clinical trials and basic science, but does not legalize ibogaine for general medical use or public access.
• Kentucky and Arizona: Similar state-level research appropriations have been proposed, but not yet enacted as of this writing.

These state initiatives signal growing interest in ibogaine's potential, but they do not override federal Schedule I restrictions. All research must still comply with federal law and obtain the necessary DEA and FDA approvals.

For a detailed overview of state-by-state psychedelic policy developments, visit our psychedelic law resource.

Safety Profile: Cardiac Risks and Clinical Considerations

Ibogaine is associated with a significant cardiac safety profile, including the risk of life-threatening arrhythmias and sudden cardiac death. These risks are a major reason for its Schedule I classification and the absence of FDA approval. Any research or clinical use of ibogaine must include rigorous cardiac screening, monitoring, and emergency protocols.

Recent cross-sectional studies have highlighted adverse health outcomes associated with ibogaine and other psychedelics. These findings inform both regulatory perspectives and clinical trial design, emphasizing the need for caution and robust safety measures in any future research or therapeutic use.

For more on psychedelic safety and research ethics, see our guides and research landscape.

Common Questions: Clinical Access, Importation, and Future Prospects

Can doctors prescribe ibogaine in the US?

No. Physicians cannot legally prescribe or administer ibogaine in the US outside of an approved research protocol. There are no legal ibogaine clinics operating in the country.

Can individuals import ibogaine for personal use?

No. Importing ibogaine is illegal under federal law and may result in criminal prosecution or seizure by US Customs and Border Protection.

Is the legal status of ibogaine likely to change soon?

While there is growing interest in psychedelic research and some progress with other substances (such as psilocybin and MDMA), ibogaine remains tightly controlled. Any change in legal status would require FDA approval and DEA rescheduling, which are lengthy and complex processes. The recent FDA call for public input on ibogaine research suggests increased regulatory attention, but does not alter its current status.

What to Do Next: Staying Informed and Navigating the Landscape

Given the complex and evolving legal landscape, researchers, clinicians, and investors should:

• Consult legal counsel before engaging in any ibogaine-related activity in the US.
• Monitor state and federal policy developments through our briefing feed.
• Explore the broader psychedelic research landscape for context on clinical trials, safety, and regulatory trends.
• Review our psychedelic law resource for detailed legal frameworks and updates.

For those considering research or investment in ibogaine, understanding the regulatory barriers and safety considerations is essential. Stay informed and proceed with caution.